Related Experiment Video
Updated: Apr 23, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug repurposing and the prior art patents of competitors
1CFH Beteiligungsgesellschaft mbH, Loehrstrasse 16, 04105 Leipzig, Germany; Ilmenau University of Technology, PATON - Landespatentzentrum Thueringen, PF 100 565, 98684 Ilmenau, Germany.
Abstract:
Drug repurposing (i.e., finding novel indications for established substances) has received increasing attention in industry recently. One challenge of repositioned drugs is obtaining effective patent protection, especially if the 'novel' indications have already been claimed by competitors within the same drug class. Here, I report the case of patents relating to phosphodiesterase type 5 (PDE5) inhibitors. Patentees of later-filed patents on novel indications (even when they could not observe prior patenting of their direct competitors) filed patents for which patent examiners did not see the prior-filed patents of the competitors as relevant prior art, whereas these follower patent applications often failed because of other reasons.
Related Concept Videos
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Prodrugs
Prodrugs help overcome...
FDA Approved Drugs: Changes to Approved Drugs
Drug Products: Biologics, Biosimilars and Interchangeables
Preclinical Development: Overview

